How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

Northwestern University economist Chuck Manski studies decision-making amid uncertainty. That prepared him better than many other cancer patients to decide whether to stay on an immunotherapy treatment that was making him very ill.